<DOC>
	<DOCNO>NCT00002152</DOCNO>
	<brief_summary>The purpose study see safe effective give WF 10 ( TCDO ) patient advance HIV disease take zidovudine , didanosine , zalcitabine , stavudine . This study also examine TCDO affect level HIV body . TCDO solution deliver vein .</brief_summary>
	<brief_title>A Study WF 10 IV Solution Patients With Advanced HIV Disease</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Approved drug stabilize dose except specifically exclude . Aerosolized pentamidine ( 300 mg ) month PCP prophylaxis . Patients must : HIV positivity . Absolute CD4 count &lt; 200 cells/mm3 . Intolerance refusal take AZT , ddI , ddC , d4T . No active opportunistic infection require ongoing therapy . Life expectancy least 3 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Neoplasm basal cell carcinoma skin . Clinically significant cardiac disease . Anemia . Concurrent Medication : Excluded : Cytotoxic chemotherapy . Corticosteroids . Patients follow prior condition exclude : History myocardial infarction arrhythmia . Prior Medication : Excluded within 2 week prior study entry : Any antiretroviral agent . Interferon . Systemic therapy biologic response modifier , corticosteroid , cytotoxic chemotherapy , neutropenic nephrotoxic drug . Excluded within 30 day prior study entry : Investigational drug . Prior Treatment : Excluded within 2 week prior study entry : Radiation therapy . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1996</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>